ArticleCancer epidemiology2025
Use of breast cancer risk reducing medications by breast cancer risk level in an older U.S. cohort.
Article in Cancer epidemiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundGuidelines recommend the breast cancer risk reducing medications (RRMs) tamoxifen, raloxifene, and aromatase inhibitors (AIs) for women at increased breast cancer risk. However, use of RRMs in this population is low. We assessed RRM trends in older women enrolled in a cancer screening trial.
methodsWe analyzed a cohort of women enrolled in the Prostate, Lung, Colorectal, and Ovarian (PLCO) screening trial who consented to linkage with Medicare files, were enrolled in Medicare Part D during 2014-2019, and for whom a breast cancer risk score could be computed. Breast cancer risk using the BCRAT model was ascertained based on questionnaire data. We assessed use of RRMs overall, by breast cancer risk level, and over time.
resultsOf 78,209 women enrolled in PLCO, 14,081 were included in the analysis cohort based on consenting to Medicare linkage and enrollment in Medicare Part D. Median (25th/75th) age in 2014 was 75(72/79). Use of any RRM during 2014-2019 was 3.6 %, with raloxifene the most common medication (3.1 %), followed by AIs (0.45 %) and tamoxifen (0.11 %). Use of any RRM, raloxifene and AIs each increased significantly with breast cancer risk level. Among women with 5-year risk ≥ 3 %, use of any RRM was 5.3 %. Over time, use of any RRM and raloxifene decreased significantly (5.7 % and 7.5 % average annual decrease, respectively); use of AIs increased significantly (16.3 %).
conclusionsUse of breast cancer RRMs was low, overall and among women with increased breast cancer risk. Overall RRM and raloxifene use decreased over time, while AI use increased.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.